Wilson R, McKillop J H, Pearson C, Burnett A K, Thomson J A
Department of Medicine, Royal Infirmary, Glasgow, UK.
Clin Exp Immunol. 1988 Aug;73(2):312-5.
Carbimazole and Propylthiouracil (PTU) are widely used in the treatment of Graves' disease, although controversy still exists as to whether or not they have any direct effect on the immune system. While many previous studies have investigated the possible effects of one or other of these drugs on the immune system only a few have directly compared the effects of equivalent doses of each drug. This study aimed to examine the effects of both drugs, during the initial 8 weeks of treatment, on various biochemical and immunological parameters. The results obtained showed that while thyroid hormone levels fell at similar rates in both treatment groups, TRAb levels and T cell subset abnormalities returned towards normal more rapidly in patients receiving Carbimazole compared to PTU. These results indicate that the effects of Carbimazole on TRAb levels and T cell subset abnormalities are not due solely to its action in controlling the biochemical features of Graves' disease and provide indirect evidence of an action on the immune system in vivo.
卡比马唑和丙硫氧嘧啶(PTU)被广泛用于治疗格雷夫斯病,尽管关于它们是否对免疫系统有直接作用仍存在争议。虽然之前许多研究调查了其中一种或另一种药物对免疫系统的可能影响,但只有少数研究直接比较了等效剂量的每种药物的效果。本研究旨在检查这两种药物在治疗的最初8周内对各种生化和免疫参数的影响。获得的结果表明,虽然两个治疗组的甲状腺激素水平以相似的速率下降,但与PTU相比,接受卡比马唑治疗的患者的促甲状腺素受体抗体(TRAb)水平和T细胞亚群异常恢复正常的速度更快。这些结果表明,卡比马唑对TRAb水平和T细胞亚群异常的影响并非仅仅归因于其控制格雷夫斯病生化特征的作用,并提供了其在体内对免疫系统有作用的间接证据。